Jones Ben J, McTaggart Steven J
Solid Organ Transplant Team, Mater Medical Research Institute, University of Queensland, Brisbane, Australia.
Exp Hematol. 2008 Jun;36(6):733-41. doi: 10.1016/j.exphem.2008.03.006.
Extensive in vitro studies have shown that multipotent mesenchymal stromal cells (MSC) can exert profound immunosuppressive effects via modulation of both cellular and innate immune pathways. Their ability to be readily isolated from a number of tissues and expanded ex vivo makes them attractive candidates for systemic immunosuppressive therapy. In this article, we will review recent experimental data on the mechanisms by which MSC inhibit the alloproliferative response and the clinical relevance for their potential use in hematopoietic stem cell transplantation, solid organ transplantation, and treatment of autoimmune diseases. While in vitro data consistently demonstrate the immunosuppressive capability of MSC, current studies in animals and humans suggest that MSC are less effective in producing systemic immunosuppression. Further mechanistic studies and randomized controlled trials using standardized cell populations are needed to define the optimal conditions for the use of MSC as immunotherapy.
广泛的体外研究表明,多能间充质基质细胞(MSC)可通过调节细胞免疫和固有免疫途径发挥显著的免疫抑制作用。它们能够轻松地从多种组织中分离出来并在体外扩增,这使其成为全身免疫抑制治疗的有吸引力的候选者。在本文中,我们将综述关于MSC抑制同种异体增殖反应的机制的最新实验数据,以及它们在造血干细胞移植、实体器官移植和自身免疫性疾病治疗中的潜在应用的临床相关性。虽然体外数据一致证明了MSC的免疫抑制能力,但目前在动物和人类中的研究表明,MSC在产生全身免疫抑制方面效果较差。需要进一步的机制研究和使用标准化细胞群体的随机对照试验来确定将MSC用作免疫疗法的最佳条件。